About Genomic Valley Biotech Limited
Data last updated:
Genomic Valley Biotech Limited is a public limited company based in Jhajjar, Haryana, India. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 16 May 1994 and has been in existence for over 32 years.
The company is registered with the Registrar of Companies (ROC), Haryana, under CIN L01122HR1994PLC033029. Its GSTIN is 06AABCG6306R1ZB (Haryana). The company holds 2 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 539206.
The company has an authorised share capital of ₹9 Cr and a paid-up capital of ₹3.05 Cr. It is led by directors including Yogesh Agrawal (Managing Director) and Satendra Kumar Goyal.
Its last annual general meeting (AGM) was held on 31 December 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 4 K.M.Stone Berri Chharra Road Vill. Kherka Musalman P.O.Tandaheri Teh Bahadu, Jhajjar, Haryana, India – 124507.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹27 Lakh, a decline of 67.9% compared to the previous year. For the same year it recorded a net profit of ₹4 Lakh (net margin 14.8%) and EBITDA of ₹5 Lakh (EBITDA margin 18.5%).
The company is associated with 1 brand: Genomic Valley Biotech. As per MCA filings, the company has satisfied charges of ₹3.74 Cr on record. The company has 17 deals on record (17 market trades); the latest was in January 2026. Its 4 peer companies in the Biotechnology industry (Agri Services, Agro Retail and Distribution, Biotechnology), with the same principal business activity (support activities to agriculture and other activities including hunting) are compared by revenue, 2 larger and 2 smaller; the largest is Sri Satsai Agro Farmer Producer Company Limited with revenue of ₹84.9 Lakh.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website genomicvalley.com.
Company details
CIN history
Genomic Valley Biotech has one previous CIN (Corporate Identification Number): L01122HR1996PLC033029. The current CIN is L01122HR1994PLC033029, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L01122HR1994PLC033029 | Current |
| L01122HR1996PLC033029 | Previous |
Contact details
Genomic Valley Biotech Limited's registered office is in Jhajjar, Haryana. Its website is genomicvalley.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address4 K.M.Stone Berri Chharra Road Vill. Kherka Musalman P.O.Tandaheri Teh Bahadu, Jhajjar, Haryana, India – 124507
- IndustryLife Sciences, Biotechnology
To see the full contact details of Genomic Valley Biotech Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Genomic Valley Biotech operates one associated brand: Genomic Valley Biotech. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| R&D company focused on plant tissue cultured plants | genomicvalley.com |
Business activity
The main business activity of Genomic Valley Biotech is agriculture, forestry, fishing. In detail, this covers support activities to agriculture and other activities including hunting.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| A | Agriculture, forestry, fishing | A4 | Support activities to agriculture and Other Activities including hunting |
To see the full business activity and turnover split of Genomic Valley Biotech Limited, buy the company report.
Financials of Genomic Valley Biotech Limited
FY 2025-26 filings availableGenomic Valley Biotech Limited reported revenue of ₹27 Lakh (down 67.9% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.27 | 0.84 | 0.17 | 2.72 | 0.07 | 0.21 | 0.85 |
| Revenue growth | -67.9% | +394.1% | -93.8% | +3785.7% | -66.7% | -75.3% | - |
| EBITDA | 0.05 | 0.43 | 0.02 | 0.62 | (0.37) | (0.14) | 0.55 |
| EBITDA margin | +18.5% | +51.2% | +11.8% | +22.8% | -528.6% | -66.7% | +64.7% |
| Profit before tax | 0.05 | 0.43 | 0.02 | 0.65 | 0.01 | (0.51) | 0.20 |
| Net profit | 0.04 | 0.34 | 0.02 | 0.91 | (0.41) | (0.57) | 0.28 |
| Net profit margin | +14.8% | +40.5% | +11.8% | +33.5% | -585.7% | -271.4% | +32.9% |
| EPS (₹) | 0.10 | 1.17 | 0.05 | 2.12 | (0.03) | (1.83) | 0.94 |
| Balance sheet | |||||||
| Total assets | - | 3.90 | 3.54 | 3.53 | 3.58 | 6.75 | 7.24 |
| Net worth | - | 3.89 | 3.54 | 3.52 | 2.87 | 4.48 | 5.04 |
| Total debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 1.55 | 1.48 |
| Cash & bank | - | 0.05 | 0.01 | 0.04 | 0.00 | 0.01 | 0.04 |
| Net working capital | - | 2.16 | 2.12 | 1.68 | 0.93 | (0.71) | (0.37) |
| Cash flow | |||||||
| Cash from operations | - | 0.03 | (0.02) | (0.78) | (2.13) | 1.48 | 0.44 |
| Cash from investing | - | 0.01 | (0.02) | 1.52 | 3.67 | (1.58) | (0.47) |
| Cash from financing | - | 0.00 | 0.00 | (0.70) | (1.55) | 0.07 | 0.00 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.04 | 0.04 | 0.05 | 0.09 | 0.09 | 0.26 | 0.22 |
| Revenue growth (YoY) | -100.0% | -55.6% | -84.6% | -77.3% | -57.1% | -43.8% | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 0.02 | 0.02 | 0.03 | 0.04 | 0.09 | 0.06 | 0.26 | 0.06 |
| EBITDA | (0.02) | 0.02 | 0.01 | 0.01 | 0.00 | 0.03 | 0.00 | 0.16 |
| EBITDA margin | - | +50.0% | +25.0% | +20.0% | 0.0% | +33.3% | 0.0% | +72.7% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.02) | 0.02 | 0.01 | 0.01 | 0.00 | 0.03 | 0.00 | 0.16 |
| Tax | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.04 | 0.04 | 0.05 | 0.09 | 0.09 | 0.26 | 0.22 |
| Revenue growth (YoY) | -100.0% | -55.6% | -84.6% | -77.3% | -57.1% | -43.8% | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 0.02 | 0.02 | 0.03 | 0.04 | 0.09 | 0.06 | 0.26 | 0.06 |
| EBITDA | (0.02) | 0.02 | 0.01 | 0.01 | 0.00 | 0.03 | 0.00 | 0.16 |
| EBITDA margin | - | +50.0% | +25.0% | +20.0% | 0.0% | +33.3% | 0.0% | +72.7% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.02) | 0.02 | 0.01 | 0.01 | 0.00 | 0.03 | 0.00 | 0.16 |
| Tax | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.27 | 0.84 | 0.17 | 2.72 | 0.07 | 0.21 | 0.85 |
| Revenue growth | -67.9% | +394.1% | -93.8% | +3785.7% | -66.7% | -75.3% | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.04 | 0.50 | 0.00 | 0.01 |
| Total expenses | 0.22 | 0.41 | 0.15 | 2.10 | 0.44 | 0.35 | 0.30 |
| Employee cost | 0.00 | 0.12 | 0.04 | 0.15 | 0.14 | 0.09 | 0.18 |
| EBITDA | 0.05 | 0.43 | 0.02 | 0.62 | (0.37) | (0.14) | 0.55 |
| EBITDA margin | +18.5% | +51.2% | +11.8% | +22.8% | -528.6% | -66.7% | +64.7% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.01 | 0.08 | 0.19 | 0.18 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.18 | 0.18 |
| Profit before tax | 0.05 | 0.43 | 0.02 | 0.65 | 0.01 | (0.51) | 0.20 |
| Tax | 0.01 | 0.09 | 0.00 | 0.00 | 0.01 | 0.06 | (0.08) |
| Net profit | 0.04 | 0.34 | 0.02 | 0.91 | (0.41) | (0.57) | 0.28 |
| Net profit margin | +14.8% | +40.5% | +11.8% | +33.5% | -585.7% | -271.4% | +32.9% |
| EPS (₹) | 0.10 | 1.17 | 0.05 | 2.12 | (0.03) | (1.83) | 0.94 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 |
| Reserves & surplus | - | 0.84 | 0.49 | 0.47 | (0.18) | 1.43 | 1.99 |
| Shareholders' funds (net worth) | - | 3.89 | 3.54 | 3.52 | 2.87 | 4.48 | 5.04 |
| Secured loans | - | 0.00 | 0.00 | 0.00 | 0.00 | 1.55 | 1.48 |
| Unsecured loans | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 1.55 | 1.48 |
| Total liabilities | - | 3.90 | 3.54 | 3.53 | 3.58 | 6.75 | 7.24 |
| Assets | |||||||
| Gross block | - | 0.01 | 0.00 | 0.48 | 2.57 | 6.60 | 5.02 |
| Net block | - | 0.01 | 0.00 | 0.00 | 1.75 | 5.86 | 4.47 |
| Capital work in progress | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.49 | 0.49 |
| Investments | - | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | - | 0.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 |
| Sundry debtors | - | 2.21 | 2.53 | 2.22 | 0.00 | 0.06 | 0.10 |
| Cash & bank balances | - | 0.05 | 0.01 | 0.04 | 0.00 | 0.01 | 0.04 |
| Loans & advances | - | 0.08 | 0.37 | 0.32 | 1.14 | 0.09 | 0.14 |
| Total current assets | - | 2.62 | 2.91 | 2.58 | 1.14 | 0.16 | 0.40 |
| Total current liabilities | - | 0.46 | 0.79 | 0.90 | 0.21 | 0.87 | 0.77 |
| Net working capital | - | 2.16 | 2.12 | 1.68 | 0.93 | (0.71) | (0.37) |
| Total assets | - | 3.90 | 3.54 | 3.53 | 3.58 | 6.75 | 7.24 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 0.01 | 0.04 | 0.00 | 0.01 | 0.04 | 0.08 |
| Net cash from operating activities | - | 0.03 | (0.02) | (0.78) | (2.13) | 1.48 | 0.44 |
| Net cash from investing activities | - | 0.01 | (0.02) | 1.52 | 3.67 | (1.58) | (0.47) |
| Net cash from financing activities | - | 0.00 | 0.00 | (0.70) | (1.55) | 0.07 | 0.00 |
| Net change in cash | - | 0.04 | (0.04) | 0.04 | (0.01) | (0.03) | (0.04) |
| Closing cash | - | 0.05 | 0.01 | 0.04 | 0.00 | 0.01 | 0.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -67.9% | +394.1% | -93.8% | +3785.7% | -66.7% | -75.3% | - |
| EBITDA growth | -88.4% | +2050.0% | -96.8% | +267.6% | -164.3% | -125.5% | - |
| PBT growth | -88.4% | +2050.0% | -96.9% | +6400.0% | +9998.0% | - | -16.7% |
| Net income growth | -88.2% | +1600.0% | -97.8% | +322.0% | +28.1% | -303.6% | - |
| Revenue CAGR (3Y) | -53.7% | +128.9% | -6.8% | +47.4% | -58.7% | -29.1% | +24.5% |
| EBITDA CAGR (3Y) | -56.8% | - | - | +4.1% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +14.8% | +40.5% | +11.8% | +23.9% | 0.0% | -271.4% | +32.9% |
| Return on capital employed | - | +12.1% | +0.6% | +25.7% | 0.0% | 0.0% | +5.4% |
| Return on net worth | - | +9.7% | +0.6% | +28.5% | 0.0% | 0.0% | +5.8% |
| Debt / equity | - | 0.00 | 0.00 | 0.00 | 0.21 | 0.32 | 0.30 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.00 | 0.21 | 0.32 | 0.30 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | -8.89 | -54.55 | 48.65 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 168.00 | 0.71 | 1.78 | 0.02 | 0.04 | 0.17 |
| Inventory turnover | - | 6.00 | 0.00 | 0.00 | 0.00 | 3.50 | 7.08 |
| Debtors turnover | - | 0.35 | 0.07 | 2.45 | 2.33 | 2.63 | 10.63 |
| EPS (₹) | 0.10 | 1.17 | 0.05 | 2.12 | (0.03) | (1.83) | 0.94 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 12.76 | 11.60 | 11.55 | 9.42 | 14.69 | 16.52 |
To see the full year-wise statements and ratios of Genomic Valley Biotech Limited, buy the company report.
Board of directors of Genomic Valley Biotech Limited
Genomic Valley Biotech has 4 current directors and 16 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Satendra Kumar Goyal Also directs: Purple Wave Infocom Limited | Director | 09 May 2024 | 2 Years 6 Months | Current |
| Parul Agrawal | Director | 14 Feb 2024 | 2 Years 8 Months | Current |
| Yogainder Kumar Gupta | Director | 30 May 2025 | 1 Years 5 Months | Current |
| Yogesh Agrawal Also directs: Genomic Valley Bharat Private Limited, Eyoge Media Entertainment Private Limited, Rishikesh School of Yoga Foundation and 2 more | Managing Director | 07 Sep 2015 | 11 Years 2 Months | Current |
Peer comparison
Genomic Valley Biotech Limited is compared with the 4 companies closest to it by revenue in the Biotechnology industry (Agri Services, Agro Retail and Distribution, Biotechnology), with the same principal business activity (support activities to agriculture and other activities including hunting), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sri Satsai Agro Farmer Producer Company Limited | ₹84.9 Lakh (FY 2024) | 158.0% | Prayagraj, Uttar Pradesh, India | |||
| Ahinsa Farmers Producer Company Limited | ₹84.88 Lakh (FY 2024) | 47.0% | Bargarh, Odisha, India | |||
| Eragudi Women Farmers Producer Company Limited | ₹84.82 Lakh (FY 2024) | 237.0% | Tiruchirappalli, Tamil Nadu, India | |||
| Agrigo Farmer Producer Company Limited | ₹84.79 Lakh (FY 2024) | 84.0% | Murtizapur, Maharashtra, India | |||
| Genomic Valley Biotech Limitedthis company | ₹27 Lakh (FY 2026) | ₹4 Lakh | 14.8% | -67.9% | Jhajjar, Haryana, India |
To see the full peer comparison of Genomic Valley Biotech Limited, buy the company report.
Auditor
Genomic Valley Biotech Limited is audited by ANDROS & CO. for the financial year 2022.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| ANDROS & CO. | FY 2022 | 008976N |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 46.10%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 53.90%.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 46.10% | 46.10% | 46.70% | 46.70% |
| Public | 53.90% | 53.90% | 53.30% | 53.30% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 27 Apr 2021 | 100439051 | Others | ₹2.26 Cr | Satisfied | |
| 30 Apr 2019 | 100282650 | Others | ₹1.48 Cr | Satisfied |
To see the full charge records of Genomic Valley Biotech Limited, buy the company report.
Total charge records: 2 View all charges
Deals & funding
Genomic Valley Biotech Limited has 17 deals on record (17 market trades); the latest was in January 2026.
Deals on record (5 of 17)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2026 | Market trade | ₹5 Lakh | Buyer: an individual |
| Oct 2024 | Market trade | ₹47.3 Lakh | Seller: an individual |
| Oct 2024 | Market trade | ₹21.3 Lakh | Seller: an individual |
| Oct 2024 | Market trade | ₹19.8 Lakh | Buyer: an individual Seller: an individual |
| Feb 2023 | Market trade | ₹8.7 Lakh | Buyer: SSR Footcare Private Limited Seller: an individual |
To see the full deal history of Genomic Valley Biotech Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Genomic Valley Biotech Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Genomic Valley Biotech Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Genomic Valley Biotech has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 06AABCG6306R1ZB | Haryana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Genomic Valley Biotech Limited, buy the company report.
Recent activity
Genomic Valley Biotech Limited has 16 board changes on record since 2012: 4 appointments and 12 cessations. The latest: Ashok Kumar ceased to be Additional Director on 15 Jan 2026.
12 earlier events are in the company report.
Frequently asked questions
Genomic Valley Biotech is an active public limited company based in Jhajjar, Haryana, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 16 May 1994 (32+ years old) and is registered under CIN L01122HR1994PLC033029. Listed on BSE: 539206.
Genomic Valley Biotech reported revenue of ₹27 Lakh for FY 2025-26 (down 67.9% YoY) based on standalone financials.
Genomic Valley Biotech has 4 current directors:
- Yogesh Agrawal - Managing Director
- Satendra Kumar Goyal - Director
- Parul Agrawal - Director
- Yogainder Kumar Gupta - Director
The latest financial statements of Genomic Valley Biotech on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 31 December 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Genomic Valley Biotech is 06AABCG6306R1ZB, registered in Haryana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Genomic Valley Biotech is L01122HR1994PLC033029. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Genomic Valley Biotech is a listed company as per MCA records. Its shares are listed on BSE (code: 539206).
Genomic Valley Biotech was incorporated on 16 May 1994, making it 32+ years old. It is registered with the Registrar of Companies, Haryana.
Genomic Valley Biotech has 17 deals on record (17 market trades); the latest was in January 2026.
The peers of Genomic Valley Biotech by revenue are Sri Satsai Agro Farmer Producer Company Limited, Ahinsa Farmers Producer Company Limited, Eragudi Women Farmers Producer Company Limited, Agrigo Farmer Producer Company Limited, all in the Biotechnology industry (Agri Services, Agro Retail and Distribution, Biotechnology), with the same principal business activity (support activities to agriculture and other activities including hunting).
Ashok Kumar ceased to be Additional Director on 15 Jan 2026. Yogainder Kumar Gupta was appointed as Director on 30 May 2025. Satendra Kumar Goyal was appointed as Director on 09 May 2024. Genomic Valley Biotech has 16 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
